Eyedrops have been the main stay for topical management of diseases of the anterior segment, including conditions such as dry eye syndrome, conjunctivitis, infections and corneal disorders. However, the distinct anatomy and physiology of the eyes result in 1-7% of drugs administered via eyedrops being retained within the eyes; with the remaining being cleared via lacrimal drainage or absorbed systemically. This increases the dosing burden of eyedrops to (in some cases), every two hours and thus has a deleterious effect on patient compliance. Ocular films have been introduced as a drug delivery intervention to enhance, sustain and control drug delivery to the eyes. The proposed research aims to revolutionise ocular drug delivery through the development of 3D printed films embedded with nanoparticles tailored for treatment of diseases of the anterior segment. The project will leverage advanced 3D printing technologies, based on current work already done within our research group [1,2], to create patient-specific ocular films capable of sustained and controlled drug release.
The films will be engineered to adhere seamlessly to the ocular surface, ensuring prolonged contact time and enhanced therapeutic outcomes. Additionally, the customisation of drug-loaded films will enable personalized treatment strategies, addressing the heterogeneity of anterior segment ocular diseases. The proposed research will involve the synthesis and optimisation of biocompatible and biodegradable polymers suitable for 3D printing, ensuring the safety and compatibility of the ocular films using cell culture of corneal epithelial cell lines. Moreover, the controlled release kinetics of various therapeutic agents will be investigated to achieve optimal therapeutic efficacy. By merging cutting-edge 3D printing technologies with pharmaceutical sciences, this research has the potential to reshape the landscape of ocular drug delivery. The development of patient-specific ocular films holds promise for enhanced treatment outcomes, reduced side effects, and improved patient adherence, ultimately advancing the field of ophthalmic medicine.
References:
- Desiato, A.; Iyire, A.; Bhogal-Bhamra, P.; Naroo, S.; Gil-cazorla, R. (2022) Optimisation and evaluation of a soluble ocular insert for sustained release of levofloxacine. Ivestigative Ophthalmology & Vision Science 63(7): 3959–A0239-3059–A0239
- Curti, C.; Kirby, D. J.; Russell, C. A (2021) Stereolithography apparatus evolution: enhancing throughput and efficiency of pharmaceutical formulation development. Pharmaceutics 13(5):616